351. Calcium/Calmodulin-Dependent Protein Kinase II Activity Persists During Chronic &bgr;-Adrenoceptor Blockade in Experimental and Human Heart Failure
- Author
-
Dewenter, Matthias, Neef, Stefan, Vettel, Christiane, Lämmle, Simon, Beushausen, Christina, Zelarayan, Laura C, Katz, Sylvia, von der Lieth, Albert, Meyer-Roxlau, Stefanie, Weber, Silvio, Wieland, Thomas, Sossalla, Samuel, Backs, Johannes, Brown, Joan H, Maier, Lars S, and El-Armouche, Ali
- Subjects
Medical Physiology ,Biomedical and Clinical Sciences ,Heart Disease ,Cardiovascular ,Aetiology ,Development of treatments and therapeutic interventions ,2.1 Biological and endogenous factors ,5.1 Pharmaceuticals ,Adrenergic beta-Antagonists ,Animals ,Calcium-Calmodulin-Dependent Protein Kinase Type 2 ,Disease Models ,Animal ,Echocardiography ,Heart Failure ,Humans ,Immunoblotting ,Metoprolol ,Mice ,Mice ,Transgenic ,beta-adrenergic blockers ,calcium ,calmodulin-dependent protein kinase type 2 ,heart failure ,calcium/calmodulin-dependent protein kinase type 2 ,Biochemistry and Cell Biology ,Cardiorespiratory Medicine and Haematology ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology ,Medical physiology - Abstract
BackgroundConsiderable evidence suggests that calcium/calmodulin-dependent protein kinase II (CaMKII) overactivity plays a crucial role in the pathophysiology of heart failure (HF), a condition characterized by excessive β-adrenoceptor (β-AR) stimulation. Recent studies indicate a significant cross talk between β-AR signaling and CaMKII activation presenting CaMKII as a possible downstream mediator of detrimental β-AR signaling in HF. In this study, we investigated the effect of chronic β-AR blocker treatment on CaMKII activity in human and experimental HF.Methods and resultsImmunoblot analysis of myocardium from end-stage HF patients (n=12) and non-HF subjects undergoing cardiac surgery (n=12) treated with β-AR blockers revealed no difference in CaMKII activity when compared with non-β-AR blocker-treated patients. CaMKII activity was judged by analysis of CaMKII expression, autophosphorylation, and oxidation and by investigating the phosphorylation status of CaMKII downstream targets. To further evaluate these findings, CaMKIIδC transgenic mice were treated with the β1-AR blocker metoprolol (270 mg/kg*d). Metoprolol significantly reduced transgene-associated mortality (n≥29; P
- Published
- 2017